Rapport Therapeutics
-
Rapport Announces Pricing of Common Stock Offering
Rapport Therapeutics (RAPP) announced the pricing of its public offering of 9,615,385 shares at $26.00 per share, potentially generating $250 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 1,442,307 shares. The offering, managed by Goldman Sachs, Jefferies, TD Cowen, and Stifel, is expected to close around September 11, 2025. Funds will support the clinical-stage biotech’s work on neurological and psychiatric disorders.
